Brian Mehling, MD has been invited to present his research at the 17th Annual World Congress of the Society for Brain Mapping and Therapeutics being held at the JW Marriott, in Los Angeles, California from Friday March 20-Sunday March 22.
The conference will bring together physicians, scientists, policy makers, funding agencies and industry to further the advances and applications in brain and spinal cord mapping and image guided therapies (operative and non-operative).
Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He conducts research in regenerative medicine and stem cell science.
His presentation is entitled Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury and the objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. “Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group,” Dr. Mehling said.
“We are focused on bringing advanced stem cell research within reach of a wider audience, “said Dr. Mehling. We support continued research into regenerative medicine,” he added.
Dr. Mehling and his colleagues are conducting clinical investigations to study adult stem cells in regenerative medicine research. These cellular products are investigational and have not been shown to be safe or effective for any disease or condition.
BHI Therapeutic Sciences supports investigational research and education in stem cell and regenerative medicine using cord blood cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Its cellular products are investigational and have not been shown to be safe or effective for any disease or condition. Multiple studies of umbilical cord blood derived stem cell research and adipose-derived stem cell research are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. BHI Therapeutic Sciences has registered stem cell research studies on ClinicalTrials.gov. Its cellular products are investigational, are not approved by the U.S. FDA, and no representation of FDA approval is made. For more information, please visit www.bhisciences.com.
The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medical device to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.
This society promotes public welfare and improves patient care through the translation of new technologies/therapies into lifesaving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and industry as well as philanthropic organization.
